Cargando…
Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism
SUMMARY: Durvalumab is a programmed cell death ligand 1 inhibitor, which is now approved in Australia for use in non-small-cell lung and urothelial cancers. Autoimmune diabetes is a rare immune-related adverse effect associated with the use of immune checkpoint inhibitor therapy. It is now being inc...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Bioscientifica Ltd
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935712/ https://www.ncbi.nlm.nih.gov/pubmed/31829972 http://dx.doi.org/10.1530/EDM-19-0098 |